Dokumente
Suchschritt : FT=beta sitosterol AND FT=bph
» Fenster schließen »

4/1 von 12 DIMDI: MEDLINE (ME60) © NLM

ND: | ME15726313
PMID: | 15726313
LR: | 20061115
CED: | 20050513
DCO: | 20050719
Autoren: | Madersbacher S; Schatzl G; Brössner C; Dreikorn K
Titel: | Phytotherapie bei BPS. Welche Präparate können heute noch verschrieben werden? Phytotherapy for BPS. Which products can still be prescribed?
Quelle: | Der Urologe. Ausg. A; VOL: 44 (5); p. 513-20 /200505/
PM: | Print
SU: | IM
Sprache: | German
CY: | Germany
JID: | 1304110
ISSN: | 0340-2592
CO: | URGABW
Institution: | Abteilung für Urologie und Andrologie, Donauspital, Wien, Osterreich. stephan.madersbacher@wienkav.at
DT: | English Abstract; Journal Article; Review
RN: | 29
Schlagwörter
CT: | CLINICAL TRIALS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS/trends; PHYTOTHERAPY/*methods; PHYTOTHERAPY/*trends; PLANT EXTRACTS/*administration & dosage; PRACTICE GUIDELINES; PROSTATIC HYPERPLASIA/complications; PROSTATIC HYPERPLASIA/*drug therapy; RISK ASSESSMENT/*methods; RISK FACTORS; TREATMENT OUTCOME; UROLOGIC DISEASES/etiology; UROLOGIC DISEASES/*prevention & control
CTG: | KLINISCHE STUDIEN; MENSCH; MÄNNLICH; ÄRZTLICHE HANDLUNGSMUSTER/Trends; PHYTOTHERAPIE/*Methoden; PHYTOTHERAPIE/*Trends; PFLANZENEXTRAKTE/*Verabreichung & Dosierung; KLINISCHE RICHTLINIEN; PROSTATAHYPERPLASIE/Komplikationen; PROSTATAHYPERPLASIE/*Arzneimitteltherapie; RISIKOABSCHÄTZUNG/*Methoden; RISIKOFAKTOREN; BEHANDLUNGSERGEBNIS; UROLOGISCHE KRANKHEITEN/Ätiologie; UROLOGISCHE KRANKHEITEN/*Verhütung & Bekämpfung
TE: | Plant Extracts
AB: | For decades, plant extracts have been amongst to the most popular drugs for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)/benign prostatic enlargement (BPE). Only a few of the many published studies meet the criteria of the WHO-BPH consensus conference. The few placebo-controlled, long-term (>/=6 months) studies suggest a positive effect of some extracts (saw palmetto, beta-sitosterol, urtica, rye-grass, saw palmetto/urtica combination) on LUTS; an effect on uroflow, post-void residual volume, prostate volume and PSA was not consistently demonstrable. Randomised trials against an active comparator (alpha1-blocker, 5alpha-reductase inhibitors) are difficult to interpret. Due to the lack of prospective studies, several meta-analyses have been published that can not, however, replace prospective studies. None of the BPH-guidelines currently recommend plant extracts, yet universally conclude that this is an interesting approach. Further prospective studies using WHO standards are required to reliably determine the role of such extracts in the management of elderly men with LUTS due to BPH/BPE.

» Volltext »
» Fenster schließen »